Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a research study to test the effectiveness of nab-paclitaxel + carboplatin +
MPDL3280A for treatment of non-small-cell lung carcinoma (NSCLC), which is a type of lung
cancer. The study aims to determine if chemotherapy combined with immune-based therapy can
lead to improvement in tumor response rates over historical response rates with chemotherapy
alone.